William G Wierda

List of Publications by Citations

172 papers	19,339 citations	69 h-index	138 g-index
180 ext. papers	22,360 ext. citations	7 avg, IF	6.25 L-index

#	Paper	IF	Citations
172	Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *New England Journal of Medicine*, **2013**, 369, 32-42	59.2	1656
171	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2016**, 374, 311-22	59.2	1164
170	Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2005**, 23, 4079-88	2.2	811
169	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. *New England Journal of Medicine*, **2020**, 382, 545-553	59.2	652
168	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. *Journal of Clinical Oncology*, **2012**, 30, 488-96	2.2	622
167	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2016**, 374, 323-32	59.2	621
166	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. *Blood*, **2008**, 112, 975-80	2.2	568
165	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. *Lancet Oncology, The*, **2016**, 17, 768-778	21.7	536
164	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*, **2015**, 125, 2497-506	2.2	529
163	Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2010**, 28, 1749-55	2.2	483
162	Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2005**, 23, 4070-8	2.2	447
161	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. *Journal of Clinical Oncology*, **2017**, 35, 826-833	2.2	442
160	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. *Lancet Oncology, The*, **2014**, 15, 48-58	21.7	372
159	Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. *Blood*, **2008**, 111, 5291-7	2.2	355
158	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. *Blood*, **2016**, 127, 303-9	2.2	347
157	CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. *Blood*, **2000**, 96, 2917-2924	2.2	294
156	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. *Lancet Oncology, The*, **2014**, 15, 1090-9	21.7	283

155	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. *Blood*, **2018**, 131, 1910-1919	2.2	267
154	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. *Blood*, **2007**, 109, 4679-85	2.2	264
153	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. *Blood*, **2009**, 114, 4441-50	2.2	260
152	Ibrutinib and Venetoclax for First-Line Treatment of CLL. *New England Journal of Medicine*, **2019**, 380, 2095-2103	59.2	256
151	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. *Blood*, **2015**, 125, 2062-7	2.2	255
150	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. *Blood*, **2008**, 112, 1923-30	2.2	254
149	High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. *Blood*, **2009**, 113, 3050-8	2.2	238
148	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2018**, 19, 65-75	21.7	228
147	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. *Nature Communications*, **2016**, 7, 11589	17.4	220
146	Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. *Blood*, **2003**, 101, 3413-5	2.2	220
145	Chronic lymphocytic leukaemia. *Nature Reviews Disease Primers*, **2017**, 3, 16096	51.1	219
144	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. *Lancet, The*, **2020**, 395, 1278-1291	40	201
143	Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. *Cancer*, **2003**, 98, 2657-63	6.4	186
142	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. *Cancer*, **2015**, 121, 3612-21	6.4	185
141	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. *Journal of Clinical Oncology*, **2018**, 36, 1973-1980	2.2	174
140	Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. *Blood*, **2007**, 110, 3316-25	2.2	170
139	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. *Blood*, **2013**, 122, 1891-9	2.2	157
138	Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. *Blood*, **2011**, 117, 3016-24	2.2	152

137	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2015**, 21, 3705-15	12.9	147
136	Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. *Blood*, **2011**, 118, 3489-98	2.2	145
135	Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. *Blood*, **2011**, 118, 5126-9	2.2	139
134	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. *Blood*, **2009**, 114, 957-64	2.2	134
133	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. *Blood*, **2009**, 113, 4637-45	2.2	132
132	Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2013**, 31, 584-91	2.2	127
131	Isoform-selective phosphoinositide 3Ŧkinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. *Blood*, **2009**, 113, 5549-57	2.2	125
130	Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter s syndrome or fludarabine-refractory chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2008**, 26, 196-203	2.2	124
129	High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. *Blood*, **2003**, 101, 4903-8	2.2	121
128	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. *Blood*, **2019**, 133, 1011-1019	2.2	120
127	Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. *Blood*, **2014**, 123, 3727-32	2.2	109
126	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. *Cancer Cell*, **2019**, 36, 369-384.e13	24.3	107
125	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. *Blood*, **2011**, 117, 6450-8	2.2	107
124	Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2011**, 29, 4088-95	2.2	105
123	Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. *Blood*, **2014**, 123, 2783-90	2.2	97
122	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. *Journal of Clinical Oncology*, **2017**, 35, 166-174	2.2	94
121	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. *Blood*, **2019**, 134, 111-122	2.2	94
120	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. *Leukemia and Lymphoma*, **2015**, 56, 1643-50	1.9	93

119	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. *Blood*, **2018**, 131, 1704-1711	2.2	93
118	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2018**, 24, 4371-4379	12.9	90
117	Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. *Blood*, **2016**, 127, 279-86	2.2	89
116	Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. *Blood*, **2011**, 117, 156-64	2.2	85
115	The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. *Blood*, **2008**, 112, 711-20	2.2	85
114	The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. *Leukemia and Lymphoma*, **2007**, 48, 1931-9	1.9	85
113	Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. *Cancer*, **2017**, 123, 2268-2273	6.4	83
112	Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. *Clinical Cancer Research*, **2017**, 23, 3734-3743	12.9	82
111	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. *Blood*, **2020**, 135, 1204-1213	2.2	81
110	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. *Lancet, The*, **2021**, 397, 892-901	40	81
109	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 1067-79	7.3	80
108	Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. *Blood*, **2010**, 115, 489-95	2.2	75
107	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. *Cancer*, **2008**, 113, 1933-52	6.4	74
106	Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. *Blood*, **2009**, 113, 3168-71	2.2	73
105	Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. *Journal of Immunology*, **2017**, 198, 1740-1747	5.3	71
104	Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. *Blood*, **2011**, 118, 2062-8	2.2	70
103	Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. *Journal of Clinical Oncology*, **2009**, 27, 1637-43	2.2	67
102	A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. *Blood*, **2018**, 132, 2249-2259	2.2	63

101	A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. *Cancer*, **2006**, 106, 337-45	6.4	56
100	Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. *Haematologica*, **2014**, 99, 1350-5	6.6	55
99	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. *Cancer*, **2019**, 125, 559-574	6.4	51
98	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 293-311	7.3	49
97	Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. *Blood*, **2011**, 118, 2085-93	2.2	49
96	Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. *Cancer*, **2013**, 119, 3805-11	6.4	48
95	Non-Hodgkin's lymphomas. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2011**, 9, 484-560	7.3	47
94	Novel immune-based treatment strategies for chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2005**, 23, 6325-32	2.2	46
93	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. *Blood*, **2020**, 135, 1859-1869	2.2	45
92	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2017**, 23, 2154-2158	12.9	43
91	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. *Blood*, **2016**, 128, 637-637	2.2	43
90	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. *Blood*, **2019**, 133, 2765-2775	2.2	42
89	Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL . *Leukemia Research*, **2010**, 34, 284-8	2.7	41
88	Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. *Cancer*, **2004**, 100, 2583-91	6.4	38
87	Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 326-62	7.3	37
86	Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. *Cancer*, **2008**, 113, 383-7	6.4	36
85	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. *British Journal of Haematology*, **2018**, 182, 504-512	4.5	32
84	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. *Blood*, **2019**, 134, 35-35	2.2	30

83	LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. *Blood*, **2011**, 117, 4076-84	2.2	28
82	AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. *Clinical Cancer Research*, **2020**, 26, 3856-3867	12.9	26
81	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. *Blood*, **2020**, 136, 16-17	2.2	26
80	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. *Blood*, **2018**, 131, 1820-1832	2.2	25
79	B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. *Molecular Cancer Research*, **2017**, 15, 1692-1703	6.6	23
78	Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. *Journal of Clinical Pharmacology*, **2014**, 54, 818-27	2.9	23
77	Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 385-91	2	22
76	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. *Clinical Cancer Research*, **2016**, 22, 2359-67	12.9	22
75	What is the best frontline therapy for patients with CLL and 17p deletion?. *Current Hematologic Malignancy Reports*, **2011**, 6, 36-46	4.4	22
74	Investigational immunotherapeutics for B-cell malignancies. *Journal of Clinical Oncology*, **2010**, 28, 884-92	2.2	21
73	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. *Blood*, **2021**, 138, 11-22	2.2	21
72	Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).. *Journal of Clinical Oncology*, **2018**, 36, 7502-7502	2.2	20
71	Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. *British Journal of Haematology*, **2019**, 187, 307-318	4.5	19
70	Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. *Modern Pathology*, **2010**, 23, 1518-23	9.8	19
69	Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. *Blood*, **2019**, 134, 1951-1959	2.2	19
68	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. *Blood*, **2021**, 137, 3327-3338	2.2	18
67	Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. *Cancer*, **2011**, 117, 116-24	6.4	17
66	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. *Journal of Clinical Oncology*, **2021**, 39, 3853-3865	2.2	17

65	Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. *Leukemia*, **2018**, 32, 2388-2398	10.7	17
64	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. *JAMA Oncology*, **2021**, 7, 1213-1219	13.4	17
63	Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. *Blood*, **2014**, 123, 3780-9	2.2	16
62	Initial therapy for patients with chronic lymphocytic leukemia. *Seminars in Oncology*, **2006**, 33, 202-9	5.5	16
61	Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. *Blood*, **2014**, 123, 1424-6	2.2	15
60	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.. *Leukemia*, **2022**,	10.7	15
59	Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. *British Journal of Haematology*, **2019**, 185, 852-864	4.5	14
58	2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. *Cancer*, **2016**, 122, 565-73	6.4	14
57	Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.. *Blood*, **2009**, 114, 207-207	2.2	14
56	Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. *Leukemia*, **2021**, 35, 3282-3286	10.7	14
55	Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. *Drugs*, **2019**, 79, 1287-1304	12.1	13
54	Current and investigational therapies for patients with CLL. *Hematology American Society of Hematology Education Program*, **2006**, 2006, 285-94	3.1	13
53	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. *Blood*, **2021**,	2.2	13
52	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. *Haematologica*, **2015**, 100, e311-4	6.6	12
51	Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 292-5	2	12
50	Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. *British Journal of Haematology*, **2015**, 170, 40-9	4.5	12
49	Ibrutinib: a paradigm shift in management of CLL. *Expert Review of Hematology*, **2014**, 7, 705-17	2.8	12
48	Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). *British Journal of Haematology*, **2010**, 148, 386-93	4.5	12

47	Genetics and molecular biology of chronic lymphocytic leukemia. *Current Treatment Options in Oncology*, **2005**, 6, 215-25	5.4	12
46	Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.. *Blood*, **2005**, 106, 719-719	2.2	12
45	An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2009**, 114, 883-883	2.2	12
44	Gene therapy and active immune therapy of hematologic malignancies. *Best Practice and Research in Clinical Haematology*, **2007**, 20, 557-68	4.2	11
43	Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL.. *Blood*, **2004**, 104, 340-340	2.2	11
42	Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. *Cancer*, **2015**, 121, 3869-76	6.4	10
41	Chronic lymphocytic leukemia: treatment options for patients with refractory disease. *Cancer*, **2009** , 115, 3830-41	6.4	10
40	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.. *Blood*, **2022**,	2.2	10
39	Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. *Leukemia*, **2019**, 33, 1663-1674	10.7	9
38	Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2014**, 55, 828-33	1.9	9
37	Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. *Clinical Cancer Research*, **2011**, 17, 4731-41	12.9	9
36	Chronic lymphocytic leukemia: new concepts for future therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10, 369-78	2	9
35	Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. *OncoImmunology*, **2018**, 7, e1417720	7.2	7
34	Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, e105-9	2	7
33	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. *Blood*, **2020**, 136, 42-43	2.2	7
32	Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients.. *Blood*, **2007**, 110, 3108-3108	2.2	7
31	Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2009**, 114, 206-206	2.2	7
30	Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. *Blood Advances*, **2020**, 4, 4508-4511	7.8	7

29	PET-positive lymphadenopathy in CLL-Not always Richter transformation. *American Journal of Hematology*, **2017**, 92, 405-406	7.1	6
28	Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2008**, 112, 45-45	2.2	6
27	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. *Blood*, **2010**, 116, 921-921	2.2	6
26	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. *Leukemia*, **2021**, 35, 3059-3072	10.7	6
25	Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. *British Journal of Haematology*, **2019**, 185, 961-966	4.5	6
24	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. *British Journal of Haematology*, **2017**, 177, 567-577	4.5	5
23	A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. *Oncotarget*, **2017**, 8, 22104-22112	3.3	5
22	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. *Leukemia*, **2021**, 35, 3421-3429	10.7	5
21	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, **2019**, 186, 184-188	4.5	5
20	A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. *British Journal of Haematology*, **2019**, 185, 606-608	4.5	5
19	Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. *Leukemia and Lymphoma*, **2021**, 62, 1129-1135	1.9	5
18	Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. *Lancet Haematology,the*, **2020**, 7, e168-e176	14.6	4
17	Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. *Leukemia and Lymphoma*, **2018**, 59, 1427-1438	1.9	4
16	Updates to the management of chronic lymphocytic leukemia. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 662-5	7.3	4
15	The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. *Journal of Experimental Pharmacology*, **2021**, 13, 923-935	3	4
14	CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. *Leukemia*, **2021**, 35, 1610-1620	10.7	4
13	Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. *Leukemia*, **2018**, 32, 2278-2281	10.7	3
12	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. *Leukemia and Lymphoma*, **2017**, 58, 348-356	1.9	2

11	The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. *British Journal of Haematology*, **2019**, 187, e1-e4	4.5	2
10	Immunologic monitoring in chronic lymphocytic leukemia. *Current Oncology Reports*, **2003**, 5, 419-25	6.3	2
9	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.. *Leukemia and Lymphoma*, **2022**, 1-9	1.9	2
8	Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.. *Leukemia*, **2022**,	10.7	2
7	Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). *Journal of Blood Medicine*, **2010**, 1, 115-22	2.3	1
6	Chronic Lymphocytic Leukemia: How to Assess Prognosis in 2007. *Clinical Leukemia*, **2007**, 1, 162-167		1
5	RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. *Leukemia*, **2021**,	10.7	1
4	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, **2021**, 194, 61-68	4.5	1
3	Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.. *Blood Cancer Journal*, **2022**, 12, 43	7	1
2	New aspects of the treatment of chronic lymphocytic leukemia. *Current Hematologic Malignancy Reports*, **2006**, 1, 251-7	4.4	
1	HLA Homozygosity and Haplotype Bias Among Patients with Chronic Lymphocytic Leukemia: Implications for Disease Control by Physiologic Immune Surveillance. *Blood*, **2010**, 116, 1370-1370	2.2	